Enabling Antibody Discovery to Therapeutics
Exclusive content from Antibody Therapeutics and Engineering US 2024San Diego, CA14 - 17 December 2024
Welcome to the post-event wrap-up of the 34th annual Antibody Engineering & Therapeutics US 2024
Introduction
Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning
Accelerating Bispecific Discovery with the Alloy Common Light Chain Fully Human Transgenic Mouse Platform
ALTHEA Libraries: Phage Display Libraries for Antibody Therapeutic Discovery and Development
Human Antibody Responses to Infection and Vaccination
Innovating Bi-specific T Cell Engagers with Nona Biosciences' HBICE® Platform
Optimizing Antibodies and Related Protein Therapeutics: Bridging AI, Experimental Designs and Developability
Revolutionizing Therapeutic Antibody Engineering with Geneious-Luma: A Path to Next-Gen Multispecific Antibodies
Xencor’s 20 Year Journey in Antibody Therapeutic Development
Accelerating Antibody Drug Discovery with GenScript's MonoRab™ & TurboCHO™ Platforms AND The Development of a Novel CD8-targeting Lipid Nanoparticle to Transiently Engineer CD8+ T Cells in vivo Using mRNA to Express a CD19 CAR
A Base-Stable Protein G Solid Phase for the Purification of Human Monoclonal Antibodies
Evolution of Stromal Niches in Inflammation, Cancer and Immunotherapy
Strategies to Amplify the Therapeutic Potential of Rabbit-derived Antibodies
Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds
Streamlined Antibody and Therapeutic Development Using The Pfenex Expression Technology® Platform
Exhibitor Spotlight
Read more of our industry reports online!